Alimera Sciences, Inc.
ATLANTA, May 20, 2010 (GlobeNewswire via COMTEX News Network) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, President and Chief Executive Officer, is scheduled to present at the Citi 2010 Global Healthcare Conference, to be held May 26-27, 2010 at The Hilton New York Hotel in New York City.
Mr. Myers and Rick Eiswirth, Chief Financial Officer, will be available to respond to questions during a breakout session immediately following the presentation and to participate in one-on-one meetings with investors attending the conference.
Event: Citi 2010 Global Healthcare Conference
Date: Thursday, May 27, 2010
Time: 3:30pm ET (Breakout: 4pm ET)
Place: The Hilton New York Hotel, New York, NY (Sutton Parlor Center)
The presentation will be webcast live through the investor relations section of Alimera Sciences' website at www.alimerasciences.com. A replay of the webcast will be available through August 25, 2010.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the Company is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
This news release was distributed by GlobeNewswire, www.globenewswire.com
--------------------------------------
CONTACT: The Ruth Group
Investors
Sara Pellegrino
646-536-7002
[email protected]
Media
Jason Rando
646-536-7025
[email protected]